Bailey G. Hannon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bailey G. Hannon has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Brandon G. Gerberich
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA
2 shared publications- C. Ross Ethier
Department of Ophthalmology, Emory University, Atlanta, USA
2 shared publications Mark R. Prausnitz
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA
2 shared publications- A. Thomas Read
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology/Emory University
1 shared publication Andrew J. Feola
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA; Center for Visual and Neurocognitive Rehabilitation, Atlanta Veteran Affairs Healthcare System, Atlanta, GA, USA
1 shared publication- Elizabeth M. Boazak
Altis Biosystems
1 shared publication
Latest Publications
- 7 November 2020
- Published by Elsevier in Experimental Eye Research
- Vol. 202, 108354
Using retinal function to define ischemic exclusion criteria for animal models of glaucoma
- 7 November 2020
- Published by Elsevier in Experimental Eye Research
- Vol. 202, 108354
Using retinal function to define ischemic exclusion criteria for animal models of glaucoma
- Open Access
- 16 October 2019
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 16 (159) , 20190427
Sustained scleral stiffening in rats after a single genipin treatment
Scleral stiffening has been proposed as a therapy for glaucoma and myopia. Previous in vivo studies have evaluated the efficacy of scleral stiffening after multiple treatments with a natural collagen crosslinker, genipin. However, multiple injections limit clinical translatability. Here, we examined whether scleral stiffening was maintained after four weeks following a single genipin treatment. Eyes from brown Norway rats were treated in vivo with a single 15 mM genipin retrobulbar injection, sham retrobulbar injection, or were left naive. Eyes were enucleated either 1 day or four weeks post-injection and underwent whole globe inflation testing. We assessed first principal Lagrange strain of the posterior sclera using digital image correlation as a proxy for scleral stiffness. Four weeks post-injection, genipin treatment resulted in a 58% reduction in scleral strain as compared to controls ( p = 0.005). We conclude that a single in vivo injection of genipin effectively stiffened rat sclera for at least four weeks which motivates further functional studies and possible clinical translation of genipin-induced scleral stiffening.
- 16 October 2019
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 16 (159) , 20190427
Open AccessSustained scleral stiffening in rats after a single genipin treatment
Scleral stiffening has been proposed as a therapy for glaucoma and myopia. Previous in vivo studies have evaluated the efficacy of scleral stiffening after multiple treatments with a natural collagen crosslinker, genipin. However, multiple injections limit clinical translatability. Here, we examined whether scleral stiffening was maintained after four weeks following a single genipin treatment. Eyes from brown Norway rats were treated in vivo with a single 15 mM genipin retrobulbar injection, sham retrobulbar injection, or were left naive. Eyes were enucleated either 1 day or four weeks post-injection and underwent whole globe inflation testing. We assessed first principal Lagrange strain of the posterior sclera using digital image correlation as a proxy for scleral stiffness. Four weeks post-injection, genipin treatment resulted in a 58% reduction in scleral strain as compared to controls ( p = 0.005). We conclude that a single in vivo injection of genipin effectively stiffened rat sclera for at least four weeks which motivates further functional studies and possible clinical translation of genipin-induced scleral stiffening.